Sean JD - Horizon Pharma Exec Counsel

Insider

Sean JD is Exec Counsel of Horizon Pharma PLC
Age 44
Phone353 1 772 2100
Webhttps://www.horizontherapeutics.com

Horizon Pharma Management Efficiency

The company has return on total asset (ROA) of 0.0444 % which means that it generated a profit of $0.0444 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0854 %, meaning that it created $0.0854 on every $100 dollars invested by stockholders. Horizon Pharma's management efficiency ratios could be used to measure how well Horizon Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Horizon Pharma PLC currently holds 2.56 B in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Horizon Pharma PLC has a current ratio of 3.88, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Horizon Pharma's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Timothy PowerBristol Myers Squibb
N/A
Michael QuigleyGilead Sciences
N/A
Victor BultoNovartis AG ADR
47
Samir MDNovartis AG ADR
62
Nadja WestJohnson Johnson
60
Thomas SchineckerRoche Holding Ltd
48
Michael KlobucharMerck Company
45
Dante BeccariaSanofi ADR
N/A
Julie BrownGlaxoSmithKline PLC ADR
62
Jonathan SymondsGlaxoSmithKline PLC ADR
62
Shobie RamakrishnanGlaxoSmithKline PLC ADR
54
Risa LavizzoMoureyMerck Company
66
Lisa LeCointeCephasMerck Company
42
Derica RiceBristol Myers Squibb
56
Bruno MnardSanofi ADR
N/A
Elaine SorgAbbVie Inc
54
Ilya YuffaEli Lilly and
49
Deborah EldracherAstraZeneca PLC ADR
59
Carrie StromAbbVie Inc
43
Sally JacksonGlaxoSmithKline PLC ADR
52
J FyrwaldEli Lilly and
61
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois Chicago, Illinois Lake Forest, Illinois South San Francisco, California Washington, D.C. Gaithersburg, Maryland Rockville, Maryland and Mannheim, Germany. Horizon Therapeutics is traded on NASDAQ Exchange in the United States. Horizon Pharma PLC (HZNP) is traded on NASDAQ Exchange in USA and employs 2,190 people.

Management Performance

Horizon Pharma PLC Leadership Team

Elected by the shareholders, the Horizon Pharma's board of directors comprises two types of representatives: Horizon Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Horizon. The board's role is to monitor Horizon Pharma's management team and ensure that shareholders' interests are well served. Horizon Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Horizon Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jane Gonnerman, Office Staff
Sean JD, Exec Counsel
Timothy Walbert, Chairman, CEO and Pres
Tina Ventura, Senior Vice President Investor Relations
Patrick McIlvenny, VP Officer
Paul Hoelscher, CFO and Executive VP of Fin.
FACP FACP, Ex Officer
Andy Pasternak, Ex Officer
Aaron Cox, Exec CFO
Geoffrey Curtis, Senior Vice President - Corporate Communications

Horizon Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Horizon Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Horizon Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Horizon Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Horizon Pharma will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Consideration for investing in Horizon Stock

If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets